Elisabeth de Darkó
Plus aucun poste en cours
Historique de carrière de Elisabeth de Darkó
Anciens postes connus de Elisabeth de Darkó
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| Yamanouchi Nordic | Directeur Technique/Scientifique/R&D | - | - |
| Conseiller Juridique Général | - | - | |
Valderm ApS
 Valderm ApS Pharmaceuticals: MajorHealth Technology Valderm ApS is focused on the development of the second generation anthracycline valrubicin for innovative once daily topical treatment of hyper proliferative skin diseases e.g. psoriasis. Preclinical studies have confirmed the anti-proliferative effect of valrubicin and an attractive safety profile upon repeated topical applications has been documented. The company was founded in 2003 and is headquartered in Lyngby, Denmark. | Directeur Général | 01/04/2006 | - |
Statistiques
Internationale
| Danemark | 3 |
Opérationnelle
| Chief Executive Officer | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
| General Counsel | 1 |
Sectorielle
| Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Valderm ApS
Valderm ApS Pharmaceuticals: MajorHealth Technology Valderm ApS is focused on the development of the second generation anthracycline valrubicin for innovative once daily topical treatment of hyper proliferative skin diseases e.g. psoriasis. Preclinical studies have confirmed the anti-proliferative effect of valrubicin and an attractive safety profile upon repeated topical applications has been documented. The company was founded in 2003 and is headquartered in Lyngby, Denmark. | Health Technology |
| Yamanouchi Nordic |
- Bourse
- Insiders
- Elisabeth de Darkó
- Expérience
